Undifferentiated pleomorphic cardiac sarcoma is a high-grade malignant mesenchymal neoplasm composed of markedly atypical, morphologically heterogeneous cells in which an adequate pathological investigation does not identify a sufficiently specific line of differentiation to assign a more precise histological subtype. The term “undifferentiated” therefore expresses a diagnostic conclusion reached through morphology, immunohistochemistry and, when indicated, molecular analysis. An inadequate specimen or a merely poorly differentiated neoplasm instead requires further investigation before receiving this classification.
The most frequently described site is the left atrium, where a polypoid component may mimic a myxoma and an infiltrative component may extend into the wall, pulmonary veins or mitral apparatus. Other locations and predominantly intramural presentations are possible. The disease mainly affects adults, across a broad age range. Its relative frequency among cardiac sarcomas is difficult to establish because historical case series used inconsistent terminology and criteria.
The former term malignant fibrous histiocytoma encompassed tumors subsequently reclassified using more precise diagnostic tools. The relationship with intimal sarcoma also involves terminological differences between classifications and studies. Clinical interpretation of a diagnosis therefore requires knowledge of the criteria applied and the investigations actually performed. This precision affects treatment selection and interpretation of the literature, in which groups bearing the same name may contain biologically distinct diseases.
The etiology of most cases remains sporadic. The presence of a cardiac sarcoma neither identifies a specific environmental exposure nor demonstrates a hereditary predisposition. Nevertheless, previous thoracic irradiation, multiple tumors, unusually young age and familial clustering of neoplasms are relevant to the initial assessment. A possible predisposition syndrome should be investigated through the appropriate genetic pathway, distinguishing germline variants from alterations present only in the tumor.
Malignant transformation is associated with disturbances of the mechanisms governing the cell cycle, genomic stability and survival. Amplification of MDM2 and CDK4, changes in growth-pathway genes and loss of regulators such as CDKN2A have been described in undifferentiated cardiac sarcomas. MDM2 may reduce p53 pathway activity, while other abnormalities converge on proliferative control. Small molecular series have identified TP53 mutations or CDKN2A deletions even in tumors without MDM2 amplification, demonstrating the heterogeneity of this category.
Intimal sarcoma and undifferentiated pleomorphic cardiac sarcoma share aspects of their morphological and molecular landscape. In the soft-tissue sarcoma literature, the former term is also used for intracavitary cardiac tumors, often with MDM2 amplification; the classification of cardiac tumors retains the category of undifferentiated pleomorphic sarcoma. This overlap should be described in the pathology report, without turning MDM2 into a simple binary criterion that alone determines the disease name. The finding must be correlated with location, architecture and the exclusion of other neoplasms.
Genomic profiling may identify alterations relevant to classification and, in selected cases, access to clinical trials. However, a mutation in a potentially druggable gene requires assessment of the specific variant, its biological role and the clinical evidence. Demonstration of an amplification does not guarantee sensitivity to its corresponding inhibitor; findings from small molecular series generate therapeutic hypotheses that must be distinguished from established indications.
Macroscopically, the tumor may appear polypoid, lobulated or diffusely infiltrative, with fleshy, hemorrhagic and necrotic areas. The portion visible within the chamber may be more conspicuous than invasion of the wall. Microscopically, pleomorphism includes spindle-shaped and epithelioid cells, nuclei of varying size and shape and, at times, multinucleated giant cells. Numerous or atypical mitoses and necrosis support its marked aggressiveness, while myxoid or inflammatory areas may complicate differentiation from other sarcomas.
In the left atrium, growth may interfere with mitral filling and produce physiology resembling valvular stenosis. Pressure is transmitted backward into the pulmonary circulation, causing dyspnea, orthopnea and potentially pulmonary edema. Invasion of one or more pulmonary venous ostia may produce regional congestion even when the transmitral gradient is modest. Cardiac output may fall because filling is obstructed while ventricular contractility remains preserved.
Myocardial infiltration alters compliance, impairs contraction and creates heterogeneous conduction. Involvement of the mitral apparatus may add regurgitation to obstruction; coronary extension may cause ischemia. Right-sided disease may impede caval return or passage through the tricuspid valve, with peripheral edema and hepatic congestion. When the process reaches the pericardium, effusion or infiltrative thickening may become the principal hemodynamic determinant.
An irregular surface favors thrombosis and embolization. Tumor fragments or adherent thrombi may leave the left heart and travel to the brain, limbs or viscera. Embolization of neoplastic material and the development of metastases are distinct events, although they can coexist. Systemic spread frequently involves the lungs and may affect other organs. Local compromise and dissemination must be considered together because a technically successful resection may leave substantial extracardiac oncological risk.
Presentation may be dominated by progressive dyspnea, reduced exercise tolerance, cough, chest pain or palpitations. Left atrial obstruction may cause rapid deterioration, including pulmonary edema, while fever, fatigue and weight loss may initially suggest an infectious or systemic illness. Syncope may reflect critical flow limitation or an arrhythmia. In other patients, diagnosis follows an embolic event or the incidental discovery of a mass on an examination performed for another reason.
The medical history should establish the rate of progression, transient neurological episodes, peripheral ischemic pain and previous procedures for cardiac masses. A lesion previously called a myxoma that recurs early, attaches at atypical sites or grows through the wall requires review of the original images and tissue. Previous neoplasms, radiotherapy, family history and conditions making thrombus or endocarditis plausible should also be documented. These findings help determine whether the heart is the primary site of disease.
Physical examination assesses pulmonary congestion, signs of impaired perfusion, murmurs, rhythm, venous pressure and edema. Left-sided involvement may cause crackles, tachypnea and a murmur due to mitral obstruction; in right-sided forms, jugular distension and hepatomegaly predominate. Focused neurological examination and assessment of peripheral pulses seek evidence of embolic consequences. Clinical findings chiefly define the severity and mechanism of injury, whereas histological subtype remains a tissue diagnosis.
Instability requires an adapted diagnostic and therapeutic sequence: critical obstruction, shock, tamponade or severe arrhythmia may require treatment before complete characterization. In a stable patient, there is time to define infiltration, spread and the sampling approach. Urgency should govern coordination of decisions while preserving the quality of information indispensable for treatment.
Transthoracic echocardiography describes size, mobility, attachment and relationships with the valves. Doppler assessment measures flow disturbance and detects regurgitation; ventricular function, estimated pulmonary pressure and effusion complete the examination. Left atrial location often makes transesophageal echocardiography useful for assessing the posterior wall, pulmonary venous ostia and mitral apparatus. A mobile component does not prove benignity and must be interpreted alongside its attachment and relationship to the wall.
Cardiac magnetic resonance imaging further evaluates the intramural component and distinguishes viable tissue, necrosis, blood and associated thrombus using a multiparametric protocol. T1 and T2 signal, perfusion and late enhancement are often heterogeneous. Cine sequences show the dynamic behavior of obstruction and residual function. Tissue characterization may strongly support malignancy, but internal variability and overlap with other sarcomas preclude identifying UPS solely on the basis of signal characteristics.
Contrast-enhanced CT helps map the pulmonary veins, coronary arteries, great vessels and mediastinal extension. The protocol must address questions affecting surgery: which walls are involved, whether the venous ostia are merely compressed or extensively occupied, and which structures would require reconstruction. Chest imaging also assesses pulmonary metastases. In patients who tolerate MRI poorly, the speed of CT may offer a significant practical advantage.
FDG PET/CT may identify suspicious extracardiac sites or a viable region for sampling. Metabolic preparation and comparison with anatomical imaging are necessary because physiological myocardial uptake and inflammation may interfere. ECG, blood count, renal and hepatic function and cardiac biomarkers, when indicated, establish the functional context and treatment safety. No blood test replaces histological classification of the mass.
The choice of sampling site is discussed after imaging. An accessible extracardiac deposit may be the safest target when it represents the same disease. With mobile left-sided masses, embolic and wall-injury risks must be balanced against the benefit of biopsy. If removal is already required because of severe obstruction and is feasible, the surgical specimen can provide diagnostic material. If preoperative or systemic treatment is planned, obtaining a reliable diagnosis before treatment becomes a priority.
Extensive sampling is essential: a pleomorphic area may represent the least differentiated component of a tumor that is otherwise classifiable. The pathologist therefore looks for regions with vascular, muscular, adipocytic or osteogenic architecture and assesses the invasive interface. Necrosis and thrombus may make a biopsy unrepresentative. A diagnosis of UPS based on a small fragment must reflect the limitations of the material and may require review after examination of the resected mass.
The immunohistochemical panel is directed at the differential diagnosis. Endothelial markers such as CD31 and ERG help identify angiosarcoma; desmin, smooth muscle actin and h-caldesmon support appropriate smooth-muscle differentiation; myogenin and MyoD1 suggest skeletal-muscle differentiation. Cytokeratins and other epithelial markers, S100 and SOX10, or lymphoid markers are selected when carcinoma, melanoma, a nerve sheath tumor or lymphoma is a realistic alternative. Isolated focal positivity may be nonspecific and requires morphological correlation.
Testing for MDM2 amplification helps clarify the relationship with the intimal sarcoma spectrum and other MDM2-amplified neoplasms. Immunohistochemistry detects the protein, whereas FISH or appropriate molecular techniques assess the gene: these results answer related but different questions. The absence of amplification does not exclude UPS. Sequencing or fusion testing may be helpful when findings suggest a specific category, such as synovial sarcoma, or when there is a defined therapeutic question.
Grade, when assessed with an applicable system such as FNCLCC, incorporates differentiation, mitoses and necrosis; high grade is consistent with the entity’s definition. Surgical specimens should document margins, extension into adjacent structures and changes related to any previous treatment. The final report should state the level of certainty, the material examined and the investigations supporting exclusion of other histological subtypes. Review by a sarcoma specialist pathologist is particularly important before initiating prolonged treatments.
Extracardiac staging primarily investigates lung metastases by CT and is extended to the abdomen, pelvis and other regions according to context and findings. The brain should be examined in patients with neurological symptoms; baseline brain imaging in asymptomatic patients with cardiac sarcoma is considered individually, taking into account risk and its implications for treatment decisions. A finding that would change a radical treatment plan to palliation may require confirmation when it can be obtained safely.
Resectability depends on whether the disease can be removed while preserving or reconstructing adequate circulatory function. Assessment includes posterior wall extension, the number and segments of pulmonary veins involved, the mitral apparatus, ventricular myocardium and extracardiac structures. A large but circumscribed tumor may offer different options from a smaller mass with multifocal infiltration. Imaging review with the surgeon should yield an operative description of the limitations and anticipated reconstructions.
Completing the assessment includes organ reserve, nutritional status, functional capacity, bleeding risk and previous oncological exposures. Left ventricular function alone describes only part of treatment tolerance: obstruction, pulmonary hypertension, right-sided failure and arrhythmias may affect safety even when ejection fraction is preserved. These findings guide the sequencing of surgery, systemic therapy and radiation treatment.
For operable localized disease, the goal is R0 resection, with microscopically clear margins. The procedure may require removal of atrial wall tissue, reconstruction of venous ostia and treatment of the mitral valve. If the tumor extends beyond the visible borders, excising only the intracavitary component carries a high risk of residual disease. R1 resection denotes microscopic margin involvement; R2 denotes gross residual disease and calls for a different assessment of subsequent objectives.
At highly experienced centers, cardiac autotransplantation may facilitate access to complex left-sided tumors through temporary explantation, resection, reconstruction and reimplantation of the same organ. This technical option is reserved for selected patients; operative risk must be weighed against oncological benefit. Donor heart transplantation raises different problems, particularly occult dissemination and immunosuppression, and is not routine treatment for an active sarcoma.
Neoadjuvant therapy may be considered if the patient is stable and a response could improve margins or make resection feasible. The period before surgery requires clinical and imaging surveillance capable of detecting progression or loss of the window of operability. When critical mitral obstruction occurs, the time needed for a response may be incompatible with hemodynamic safety, making surgery the priority.
Doxorubicin remains a reference treatment for many advanced soft-tissue sarcomas. Combination with ifosfamide may be discussed when a higher probability of tumor shrinkage has concrete clinical value and the patient's reserve allows the toxic burden. In the heart, treatment choice requires an especially careful balance between antineoplastic activity and cardiotoxicity. Subsequent lines may include gemcitabine-containing regimens, including combinations with docetaxel, or pazopanib when appropriately indicated, adapting the sequence to response, comorbidities and previous therapy.
The adjuvant decision after resection incorporates systemic risk, margins, location of possible residual disease and cumulative toxicity. The lack of randomized trials specific to cardiac UPS limits the ability to prescribe a single uniform approach. Radiotherapy may help control selected residual disease or recurrence, but proximity to healthy myocardium, coronary arteries and valves requires motion- and dose-aware planning. Benefits demonstrated for limb sarcomas cannot be directly transferred to the same dose and sequence in the heart.
Immunotherapy has shown activity in some extracardiac UPS cases and is also being studied in perioperative strategies. A phase II trial evaluated nivolumab, alone or with ipilimumab, combined with radiotherapy in the cohort with extremity or truncal UPS, and documented pathological responses. This evidence supports the research rationale, whereas the efficacy and safety of such regimens in cardiac disease require specific evaluation. Relevant biomarkers, clinical protocols and discussion within an expert team guide any proposal; the UPS label alone or isolated PD-L1 positivity does not guarantee benefit.
In tumors with selected molecular alterations, targeted therapies are considered according to evidence for that precise alteration and the availability of approved indications or trials. MDM2 inhibitors and other strategies targeting growth pathways belong to a research or specialist-selection setting, rather than following automatically from a pathology report. For oligometastatic disease or an isolated recurrence, further local treatment may be discussed after evaluating the disease-free interval, distribution and feasibility of controlling all significant sites.
Cardio-oncology management accompanies treatment with surveillance of function, rhythm, blood pressure and biomarkers when indicated. Heart failure treatment and any cardioprotection are adapted to the patient's physiology and oncological regimen. Anticoagulation, pericardial drainage or palliative surgery have specific indications. Pain management, nutrition, rehabilitation and early palliative care can improve treatment tolerance and quality of life throughout the different stages of disease.
The disease course is burdened by local recurrence and metastatic spread. Resectability, initial extent, residual disease, response and cardiac reserve affect outcomes; the independent prognostic meaning of individual molecular alterations remains less defined. Series separating intimal sarcoma from UPS yield results not directly comparable with those grouping them together. The advantage associated with surgery in retrospective series is also influenced by selection of patients with more favorable disease and clinical conditions.
Surveillance combines echocardiography and MRI of the treated site with extracardiac imaging, especially of the chest, according to risk and treatment phase. Assessment of a residual mass takes account of perfusion, scar, necrosis and possible thrombus; clinical response includes gradients, congestion and function as well as size measurements. Follow-up is more frequent during early high-risk periods and should be brought forward if new dyspnea, embolism, syncope or rhythm disturbances occur. Duration and intervals are individualized by the treating team.
Major complications include obstructive pulmonary edema, valvular insufficiency, low cardiac output, arrhythmias, cerebral or peripheral embolization and tamponade. Invasion may compromise coronary arteries and conduction tissue; metastases damage organs according to their location. Persistent superimposed thrombus may increase embolic risk, while bleeding or an impending procedure changes the antithrombotic risk–benefit balance.
After treatment, reconstruction-related complications, ventricular dysfunction, residual venous stenosis, valvular problems or conduction disturbances may occur. Chemotherapy, targeted agents and immunotherapy add specific risks, including bone marrow and organ toxicity and, with checkpoint inhibitors, immune-mediated events that may also affect the heart. Distinguishing toxicity, anatomical consequences and tumor recurrence allows the strategy to be adjusted to the actual problem.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.